---
title: "Design Therapeutics Provides RESTORE-FA Clinical Development Update and Reports Second Quarter 2026 Financial Results"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294692386.md"
description: "The RESTORE-FA trial is advancing with modifications following promising results after four weeks of dosing. The forthcoming data, based on 12 weeks of dosing, is anticipated to be unveiled in the first quarter of 2027."
datetime: "2026-08-03T12:03:49.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294692386.md)
  - [en](https://longbridge.com/en/news/294692386.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294692386.md)
generator: "portal-rs"
---

# Design Therapeutics Provides RESTORE-FA Clinical Development Update and Reports Second Quarter 2026 Financial Results

The RESTORE-FA trial is advancing with modifications following promising results after four weeks of dosing. The forthcoming data, based on 12 weeks of dosing, is anticipated to be unveiled in the first quarter of 2027.

### Related Stocks

- [DSGN.US](https://longbridge.com/en/quote/DSGN.US.md)

## Related News & Research

- [Design Therapeutics management joins Cantor Fitzgerald Global Healthcare Conference fireside chat](https://longbridge.com/en/news/297782411.md)
- [Is First Advantage’s AI Push and Sterling Integration Quietly Redefining Its Profit Story (FA)?](https://longbridge.com/en/news/297812308.md)
- [Somec unit Fabbrica wins 83,600-sq-m facade contract for New York’s 350 Park Avenue](https://longbridge.com/en/news/298271753.md)
- [Curanex Pharmaceuticals executes 1-for-20 reverse stock split](https://longbridge.com/en/news/298072376.md)
- [Is Dutch Bros (BROS) Undervalued Following Its Earnings Beat And Sharp Sell Off?](https://longbridge.com/en/news/297914616.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**